OM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Outset Medical Inc (OM) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals or recent news to drive momentum. While analysts maintain a Buy rating, the reduced price targets and lack of immediate growth indicators suggest a cautious approach.
The stock is trading pre-market at $3.52, slightly above the pivot point of $3.458. The MACD is positive but contracting, RSI is neutral at 56.747, and moving averages are converging, indicating no clear trend. Support levels are at $3.246 and $3.116, while resistance levels are at $3.67 and $3.801.
Analysts note stability in the salesforce, a new product pipeline, strong recurring revenue, and improving margins. Gross margin increased by 16.15% YoY.
Analysts have lowered price targets. No recent news or trading activity from insiders, hedge funds, or Congress. The stock has a high implied volatility percentile (90.44), indicating uncertainty.
In Q4 2025, revenue dropped by 2.01% YoY to $28.87M, net income fell by 23.98% YoY to -$19.49M, and EPS dropped by 85.32% YoY to -1.07. Gross margin improved to 42.36%, up 16.15% YoY.
Analysts maintain a Buy rating but have lowered price targets (BTIG: $15 from $17, TD Cowen: $12 from $15). Analysts highlight a solid quarter for rebuilding credibility but note the company's results met expectations without exceeding them.
